Those investments included a 67 million pound upgrade to GSK's manufacturing site in Montrose, Scotland, to beef up production of active pharmaceutical ingredients.

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...